SEC Form 4
10x Genomics, Inc. (TXG) insider trading
In the 12 months to Oct 26, 2026, 5 TXG insiders reported open-market sales of $11.5M across 15 filings; no open-market purchases were filed.
Latest filing · Last 12 months · Source: SEC EDGAR · How we count
- Open-market sales
- $11.5M
- 15 filings · 5 insiders
- Open-market purchases
- $0
- 0 filings
- Pre-arranged sales (10b5-1)
- 13 of 15
- $9.1M of $11.5M sold (79%)
Who traded TXG, and when
- Sale
- Sale, pre-arranged (10b5-1)
TXG daily close from Oct 27, 2025 to Oct 26, 2026, between $12.44 and $97.74, last $72.42. 15 sale and 0 purchase filings by 5 insiders, marked at their filing dates. Serge Saxonov, Chief Executive Officer: sold $4.8M across 7 filings, first filed Mar 4, 2026, last Sep 24, 2026. Adam Taich, Chief Financial Officer: sold $3.0M across 1 filing, first filed Sep 11, 2026, last Sep 11, 2026. John R. Stuelpnagel, Director: sold $2.4M across 2 filings, first filed Aug 13, 2026, last Sep 8, 2026. Shehnaaz Suliman, Director: sold $791.9K across 3 filings, first filed Jun 18, 2026, last Sep 24, 2026. Sarah A. Teichmann, Director: sold $579.4K across 2 filings, first filed Feb 27, 2026, last Aug 17, 2026.
Largest mark · tap a row for others
Adam Taich · Chief Financial Officer
Sale $2,995,470
46,388 shares at $64.57 avg
Filed Sep 11, 2026 · traded Sep 9
Pre-arranged (10b5-1) · close on filing date $68.59
Serge Saxonov · Chief Executive Officer
Chief Executive Officer
$4.8M soldAdam Taich · Chief Financial Officer
Chief Financial Officer
$3.0M soldJohn R. Stuelpnagel · Director
Director
$2.4M soldShehnaaz Suliman · Director
Director
$791.9K soldSarah A. Teichmann · Director
Director
$579.4K soldOpen-market trades
15 filings in the last 12 months| Insider | Role | Sold | Bought | Filings | Pre-arranged (10b5-1) | Last filed |
|---|---|---|---|---|---|---|
| Serge Saxonov | Chief Executive Officer | $4.8M | — | 7 | 100% of sales | |
| Adam Taich | Chief Financial Officer | $3.0M | — | 1 | 100% of sales | |
| John R. Stuelpnagel | Director | $2.4M | — | 2 | — | |
| Shehnaaz Suliman | Director | $791.9K | — | 3 | 100% of sales | |
| Sarah A. Teichmann | Director | $579.4K | — | 2 | 100% of sales |
| Filed | Insider | Type | Shares | Avg price | Value | Held after | Source |
|---|---|---|---|---|---|---|---|
traded | Serge Saxonov Chief Executive Officer | SalePre-arranged (10b5-1) | 25,000 | $81.22 | $2.0M | 1,050,249 | |
traded | Shehnaaz Suliman Director | SalePre-arranged (10b5-1) | 5,723 | $81.19 | $464.7K | 28,609 | |
traded | Adam Taich Chief Financial Officer | SalePre-arranged (10b5-1) | 46,388 | $64.57 | $3.0M | 316,344 | |
traded | John R. Stuelpnagel Director | Sale | 20,000 | $61.75 | $1.2M | 328,436 | |
traded | Serge Saxonov Chief Executive Officer | SalePre-arranged (10b5-1) | 10,486 | $63.69 | $667.9K | 1,082,335 | |
traded | Shehnaaz Suliman Director | SalePre-arranged (10b5-1) | 2,207 | $63.65 | $140.5K | 29,515 | |
traded | Sarah A. Teichmann Director | SalePre-arranged (10b5-1) | 7,551 | $57.25 | $432.3K | 28,058 | |
traded | John R. Stuelpnagel Director | Sale | 20,000 | $57.75 | $1.2M | 348,436 | |
traded | Serge Saxonov Chief Executive Officer | SalePre-arranged (10b5-1) | 30,000 | $34.44 | $1.0M | 1,129,853 | |
traded | Shehnaaz Suliman Director | SalePre-arranged (10b5-1) | 5,723 | $32.63 | $186.8K | 32,086 | |
traded | Serge Saxonov Chief Executive Officer | SalePre-arranged (10b5-1) | 10,718 | $24.71 | $264.8K | 1,138,380 | |
traded | Serge Saxonov Chief Executive Officer | SalePre-arranged (10b5-1) | 5,000 | $24.56 | $122.8K | 1,167,273 | |
traded | Serge Saxonov Chief Executive Officer | SalePre-arranged (10b5-1) | 15,000 | $19.26 | $288.9K | 1,172,273 | |
traded | Serge Saxonov Chief Executive Officer | SalePre-arranged (10b5-1) | 16,152 | $22.73 | $367.1K | 1,203,667 | |
traded | Sarah A. Teichmann Director | SalePre-arranged (10b5-1) | 7,579 | $19.41 | $147.1K | 26,780 |
GET /stocks/filings/vX/form-4?tickers=TXG&filing_date.gte=2025-10-26&sort=filing_date.desc&limit=500{
"status": "OK",
"results": [
{
"tickers": [
"TXG"
],
"issuer_cik": "0001770787",
"owner_cik": "0001786720",
"accession_number": "0001610717-26-000421",
"form_type": "4",
"filing_date": "2026-09-24",
"period_of_report": "2026-09-22",
"issuer_name": "10x Genomics, Inc.",
"issuer_trading_symbol": "TXG",
"owner_name": "Saxonov Serge",
"is_director": true,
"is_officer": true,
"is_ten_percent_owner": false,
"is_other": false,
"officer_title": "Chief Executive Officer",
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Class A Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": true,
"transaction_date": "2026-09-22",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 9300,
"transaction_price_per_share": 80.9033,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 1062949,
"transaction_value": 752400.6900000001,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F1",
"description": "The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on November 29, 2025."
},
{
"id": "F4",
"description": "This transaction was executed in multiple trades at prices ranging from $80.28 to $81.27, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."
}
]
},
{
"tickers": [
"TXG"
],
"issuer_cik": "0001770787",
"owner_cik": "0001786720",
"accession_number": "0001610717-26-000421",
"form_type": "4",
"filing_date": "2026-09-24",
"period_of_report": "2026-09-22",
"issuer_name": "10x Genomics, Inc.",
"issuer_trading_symbol": "TXG",
"owner_name": "Saxonov Serge",
"is_director": true,
"is_officer": true,
"is_ten_percent_owner": false,
"is_other": false,
"officer_title": "Chief Executive Officer",
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Class A Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": true,
"transaction_date": "2026-09-22",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 9900,
"transaction_price_per_share": 81.8254,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 1053049,
"transaction_value": 810071.46,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F1",
"description": "The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on November 29, 2025."
},
{
"id": "F5",
"description": "This transaction was executed in multiple trades at prices ranging from $81.28 to $82.25 inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."
}
]
}
]
}
// trimmed to 2 resultsThe response includes every Form 4 record; this page keeps open-market purchases and sales on common stock and removes duplicate joint-filer rows.
Other insider activity (not market trades) · 25 records
- Option exercises1 record
- Tax withholding (sold to cover)12 records
- Grants and awards9 records
- Gifts3 records
Reported on Form 4 but not purchases or sales in the market, so not counted in the totals above.
How to read this page
- Open-market purchase or sale
- A buy or sell of the company's stock at market price. Grants, option exercises, shares withheld for tax, gifts and employee stock plan purchases are listed separately and not counted.
- Pre-arranged (10b5-1)
- The insider marked the filing as made under a trading plan set up in advance (SEC Rule 10b5-1). The mark covers the whole filing, and an unmarked filing may still be under a plan.
- Filing date
- Insiders have two business days to report a trade. Totals and the chart use the filing date, when the trade became public.
Frequently asked questions
Has 10x Genomics, Inc.'s CEO sold stock?
Yes. Serge Saxonov (CEO) sold 112,356 shares ($4.8M) between Mar 2026 and Sep 2026, all under a pre-arranged 10b5-1 plan.
How current is TXG’s insider data?
These are TXG Form 4 filings from the last year, refreshed daily. The Massive Form 4 API has the full, continuously updated record.
What counts as an open-market buy or sell?
Only purchases and sales at the market price. Option exercises, grants, gifts, and shares withheld for taxes are reported on Form 4 but are left out of the buy and sell totals.
Build with AI
Track TXG insider trades with your agent
This page joins two Massive endpoints: Form 4 filings and daily prices. Ask an agent to watch for new filings:
Using the Massive API (massive.com/docs/llms.txt), check Form 4 filings for TXG every day with transaction_code=P and tell me when an insider files an open-market purchase, with their role, shares, price and the filing link.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.